Efzofitimod is under clinical development by aTyr Pharma and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Efzofitimod’s likelihood of approval (LoA) and phase transition for Pulmonary Sarcoidosis took place on 22 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Efzofitimod Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Efzofitimod overview

efzofitimod (ATYR-1923) is under development for the treatment of rare pulmonary diseases with an immune component (RPIC) including interstitial lung diseases such as chronic hypersensitivity pneumonitis and connective tissue diseases (CTD-ILD), pulmonary sarcoidosis and coronavirus disease 2019 (COVID-19) with severe pneumonia. It is administered by intravenous route. The drug candidate targets neuropilin-2. The drug candidate constitutes an immunoglobin Fc fused with the immuno-modulatory domain (iMod domain) of histidine aminoacyl tRNA synthetase (HARS).

aTyr Pharma overview

aTyr Pharma is a clinical-stage biotechnology company. It is engaged in the discovery and clinical development of medicines for the treatment of cancer and lung diseases. Its ATYR1923 is a clinical-stage product candidate, based on the resokine pathway, which binds to the neuropilin-2 receptor harnesses immune engagement in interstitial lung diseases and other immune-mediated diseases. It also concentrates on research and development of extracellular functionality of tRNA synthetases. aTyr Pharma also develops drugs for cancer, inflammation, neurodegenerative diseases, and metabolic disorders. The company collaborates with research institutions for its research and development activities. aTyr Pharma is headquartered in San Diego, California, the US.

Quick View Efzofitimod LOA Data

Report Segments
  • Innovator
Drug Name
  • Efzofitimod
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Immunology
  • Infectious Disease
  • Musculoskeletal Disorders
  • Respiratory
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.